Cancer immunotherapies
by design

iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.

At iTeos, we specialize in targeted immunotherapies for people living with cancer.

We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.

Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.

As a responsible company, we are committed to building Environmental, Social and Governance (ESG) principles into how we operate to create sustainable value for society and all of our stakeholders.

cancer patient wearing headscarf

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

EOS-448

Following is a list of drug combinations currently under study with EOS-448, as well as the indication for each.

drug combo and indication:

+ dostarlimab | 1L NSCLC PDL1high

status of study phases:

Phase 2, active

drug combo and indication:

+ dostarlimab | 1L HNSCC PDL1high / low

status of study phases:

Phase 2, active

drug combo and indication:

+ dostarlimab + CD96 | Advanced Malignancies

status of study phases:

Phase 1, active

drug combo and indication:

+ dostarlimab + Inupadenant | Advanced Malignancies

status of study phases:

Phase 1, planned

drug combo and indication:

+ Inupadenant | Advanced Malignancies

status of study phases:

Phase 2, active

drug combo and indication:

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

status of study phases:

Phase 2, active

Inupadenant

Following is a list of drug combinations currently under study with Inupadenant, as well as the indication for each.

drug combo and indication:

Monotherapy | High Biomarker

status of study phases:

Phase 2, active

drug combo and indication:

+ pembrolizumab | PD-1 Resistant Melanoma

status of study phases:

Phase 2, active

drug combo and indication:

+ chemotherapy | 2L Chemo-naive NSCLC

status of study phases:

Phase 2, active

EOS-984

Following is a list of drug combinations currently under study with EOS-984, as well as the indication for each.

drug combo and indication:

IND Enabling Studies

status of study phases:

Preclinical, active

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

There has never been a better time to work at iTeos.

As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.

Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.

scientist working in a lab

Latest press releases

See all press releases